Patheon said it will be exhibiting and showcasing their biological service offerings at the BIO International Convention in San Diego, Calif., between June 23-26.
According to a company release, DPx Holdings B.V. emerged as a result of a $2.6 billion deal between Patheon and Royal DSM's Pharmaceutical Products business.
Dr. Manja Bouman, President, Biologics and BioSolutions, Patheon, shared, "We understand our clients' challenges to develop and manufacture biological drugs and also the challenges of our biotech customers to finance their research and development programs, and we are constantly looking for ways to help address these issues. By opening our mammalian cGMP production facility in Brisbane, Australia, in 2013, we now offer our customers a state-of-the-art, full disposable drug substance manufacturing facility in addition to the sterile fill-finish capabilities in Monza and Ferentino, Italy, and Greenville, N.C., USA."
Bouman goes on to highlight, "The facility in Brisbane also provides the ability for companies to apply for a 45 percent cash rebate program through the Australian Tax Office for eligible R&D programs including development and manufacturing work and clinical trial studies. To be eligible for this rebate program, minimally 50 percent of the development program needs to be performed in Australia. The financial benefit to biotech customers that the Australian government offers in combination with manufacturing at Patheon Brisbane is significant and provides an alternative way to help finance biotech companies."
"BioPharmaceuticals Australia is committed to supporting endeavors to build the client pipeline in the new facility," said David Hughes, CEO BPA. "We foresee Patheon biologic capabilities and services investment locally as a key contributor to a thriving biotech cluster based upon Australia's advantages for accelerated clinical development."
More information and complete details:
((Comments on this story may be sent to email@example.com))